Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "PharmaJet"

7 News Found

Covestro and PharmaJet work to take the sting out of vaccinations
Biotech | April 07, 2022

Covestro and PharmaJet work to take the sting out of vaccinations

Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization


Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D
News | February 02, 2022

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D

The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST


ZyCoV-D to be initially administered in seven states
News | December 02, 2021

ZyCoV-D to be initially administered in seven states

The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20


Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D
News | November 25, 2021

Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D

The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022


Cadila Healthcare signs agreement with Shilpa Medicare for production of ZyCoV-D
News | September 26, 2021

Cadila Healthcare signs agreement with Shilpa Medicare for production of ZyCoV-D

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus


Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine
News | September 13, 2021

Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine

The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.


Zydus applies to the DCGI for EUA to launch ZyCoV-D
News | July 01, 2021

Zydus applies to the DCGI for EUA to launch ZyCoV-D

ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials